IL-2, IL-9, IL-15 Inhibitor
The Company’s lead development candidate, BNZ-1, is a selective inhibitor of cytokines IL-2 and IL-15 that are potent T-lymphocyte growth factors and key disease drivers in many T-cell Leukemias. T lymphocyte malignancies (T-cell Leukemias), include a group of rare and often aggressive leukemias with limited treatment options and poor prognosis.
With a dual mechanism of action, the inhibition of IL-15 prevents the proliferation of IL-15 dependent leukemic cells while an IL-2 blockade eliminates the inhibitory check on Treg cells whose function is to suppress internal immune responses against ‘self cells’, including tumors.
BNZ-1 is currently in Phase 1 studies.